Research Article
Improvement by Medication Less than Expected in Parkinson’s Disease: Blinded Evaluation of Levodopa Response
Table 3
Motor function and test results for patients with PD divided after the measured medicine effect.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PD LDCT ≤ 30%, PD acute levodopa challenge test with a change less than or equal to 30% improvement of UPDRS III; PD LDCT > 30%, PD acute levodopa challenge test with more than 30% improvement of UPDRS III; UPDRS, Unified Parkinson’s Disease Rating Scale; LEDD, Levodopa Equivalent Daily Dose; ADL, Schwab and England Activities of Daily Living Scale; BDI, Beck’s Depression Inventory. The total daily L-dopa equivalent dose (LEDD) for each patient is calculated by using the conversion factors form Tomlinson [10]. We did not distinguish between L-dopa medicines with immediate or controlled release. All values are reported as the median (minimum, maximum) or absolute frequency (relative frequency in %). |